Sulindac
Mostrando 1-12 de 25 artigos, teses e dissertações.
-
1. The neuroprotective effect of Sulindac after ischemia-reperfusion injury in rats
PURPOSE: To investigate the neuroprotective effects of Sulindac on the hippocampal complex after global cerebral ischemia/reperfusion (I/R) injury in rats.METHODS: Thirty one Sprague-Dawley rats were used, distributed into group I (sham) n:7 were used as control. For group II (n:8), III (n:8) and IV (n:8) rats, cerebral ischemia was performed via the occlusi
Acta Cir. Bras.. Publicado em: 2014-04
-
2. Preparação e caracterização de materiais híbridos bioinorgânico-orgânicos contendo metalofármacos de cobre-naproxeno e de cobre-sulindaco em acetato de celulose / Preparation and characterization of bioinorganic-organic hybrid materials containing copper-naproxen and copper-sulindac metallodrugs into cellulose acetate
A bioatividade de complexos metálicos é de grande interesse atual na área de pesquisa de novos medicamentos. Fármacos anti-inflamatórios não-esteróides (FAINEs) são amplamente consumidos para o tratamento de doenças inflamatórias e de dor, mas seu contínuo uso pode ocasionar sérios efeitos colaterais ao trato gastrointestinal (TGI). Metalofármac
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 08/07/2011
-
3. Estudo de metalofármacos antiinflamatórios de cobre e dos materiais híbridos resultantes de suas imobilizações no hidróxido duplo lamelar hidrotalcita: síntese, caracterização e avaliação da atividade farmacológica / Studies of Anti-inflammatory Copper-based Drugs and Corresponding Hybrid Materials from their Immobilization on the Layered Double Hydroxide Hydrotalcite: Synthesis, Characterization and Evaluation of Pharmacological Activities
Non-steroidal anti-inflammatory drugs are widely consumed to treat inflammatory diseases and pain but their clinical use are limited due to serious side-effects on the gastrointestinal tract. The bioactivity of metal complexes exhibits great interest in metal-based drug research. Cu(II)-NSAID compounds show good anti-inflammatory property and decreased side-
Publicado em: 2007
-
4. Study of the toxicity induced by the anti-inflammatory sulindac and its metabolites, sulindac sulfone and sulindac sulfide / Estudo da toxicidade induzida pelo antiinflamatório sulindaco e seus metabólitos sulfona e sulfeto
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) known to inhibit non-selectively ciclooxygenases (COX) 1 and 2. Sulindac is therapeutically used as anti-inflammatory and analgesic in the symptomatic treatment of acute and chronic rheumatoid arthritis, osteoarthritis, and ankylosing spondylits. In addition to this property, a role in the prevention/
Publicado em: 2006
-
5. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells.
Nonsteroidal antiinflammatory drugs (NSAIDs), have cancer preventive and tumor regressive effects in the human colon. They lower the incidence of and mortality from colorectal cancer and sulindac reduces the number and size of polyps in patients with familial adenomatous polyposis. We studied the effect of sulindac, and its metabolite sulindac sulfide, on th
-
6. Sulindac confers high level ischemic protection to the heart through late preconditioning mechanisms
We have recently shown that sulindac, an anti-inflammatory drug, enhances the killing of cancer cells, but not normal cells, under conditions of oxidative stress, by mechanisms unrelated to its cyclooxygenase (COX) inhibition. To further study the protective effect of sulindac on cells exposed to oxidative stress, we have investigated the effect of sulindac
National Academy of Sciences.
-
7. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations
We have previously reported that sulindac, a non-steroidal anti-inflammatory drug, inhibited tumor formation in the small intestine but increased tumors in the colon of ApcMin/+ mice, a model of human familial adenomatous polyposis. To further explore intestinal regional responses, we studied effects of sulindac on additional gene-targeted mouse models of hu
Oxford University Press.
-
8. Effects of sulindac on sporadic colorectal adenomatous polyps.
BACKGROUND: Although sulindac is known to cause regression of colorectal adenomatous polyps in familial adenomatous polyposis, less is known about the effect of sulindac on sporadic adenomas. The precise mechanisms of these effects also remain to be determined. AIMS: Sulindac was given to patients with sporadic colorectal adenomatous polyps to evaluate its e
-
9. Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice
Neointimal hyperplasia is a critical component of restenosis, a major complication of angioplasty and related therapeutic procedures. We studied the effects of hyperlipidemia and the nonsteroidal anti-inflammatory drugs, aspirin (acetyl-salicylic acid; ASA), and sulindac, on neointimal formation in a mouse femoral arterial injury model. At 2 months of a
The National Academy of Sciences.
-
10. Sulindac. Trials of a new anti-inflammatory drug.
Trials in patients with rheumatoid arthritis and osteoarthritis showed sulindac to be an analgesic with anti-inflammatory properties and at least as effective as aspirin. It was effective within 24 hours in doses of 300-400 mg daily. It had the advantages of twice daily administration and a lower incidence of gastric side effects than aspirin. Constipation,
-
11. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection
Nonsteroidal anti-inflammatory drugs (NSAIDs) are well-known cancer preventives, which have been largely attributed to their antiproliferative and apoptosis-inducing activities. In this study, we show that microsatellite instability (MSI) in colorectal cancer cells deficient for a subset of the human mismatch repair (MMR) genes (hMLH1, hMSH2, and hMSH6), is
The National Academy of Sciences.
-
12. Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients
BioMed Central.